Peptides for Shar-Pei ibd and gut health
The short answer
Shar-Peis carry an elevated predisposition to ibd and gut health. The compounds investigated for it are BPC-157. At a typical Shar-Pei weight of 18–27 kg (40–60 lb), this breed falls in the medium breed dosing class.
IBD and gut health in Shar-Peis
Canine inflammatory bowel disease is a chronic inflammatory infiltration of the gut wall producing intermittent vomiting, diarrhoea, and weight loss despite a normal appetite. Diagnosis requires excluding parasites, dietary responsiveness, and infectious causes, and management usually combines diet with immunomodulation. BPC-157 is the compound of interest here for a specific reason: it was originally isolated from gastric juice, and a substantial share of the published research concerns protection and repair of the gastrointestinal lining rather than musculoskeletal tissue.
Dosing at Shar-Pei body weight
Calculated for a 23 kg (51 lb) dog — the midpoint of the typical range for this breed.
| Compound | Dose at 23 kg | Frequency | Evidence |
|---|---|---|---|
| BPC-157 | 46–230 mcg | Once daily | Emerging evidence |
Weigh your dog rather than using a breed average — an individual Shar-Pei can sit well outside the typical range. Use the dose calculator for an exact figure.
Common questions
What peptides are used for ibd and gut health in Shar-Peis?+
BPC-157 are investigated for ibd and gut health. No breed-specific pharmacological restriction is established for Shar-Peis among these compounds.
How much should a Shar-Pei be given?+
Shar-Peis typically weigh 18–27 kg (40–60 lb), placing them in the medium breed class. BPC-157: approximately 46–230 mcg at 23 kg. Weigh your dog rather than relying on a breed average.
Are Shar-Peis more prone to ibd and gut health?+
Yes. Shar-Peis carry an elevated predisposition to ibd and gut health. Chronic inflammation of the intestinal lining causing vomiting, diarrhoea, and weight loss.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
Other conditions Shar-Peis are predisposed to: Skin and coat.
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.